A AGILENT TECHNOLOGIES, INC.
Laboratory Analytical Instruments · NYSE · SEC CIK 1090872 · Fiscal year ends 10/31
Financial factors as of 2026-07-31 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.6%
TTM net income YoY18.0%
TTM EPS YoY18.5%
Revenue 3-yr CAGR1.8%
Net income 3-yr CAGR8.3%
Margins
Gross margin53.8%
Operating margin22.2%
Net margin19.5%
FCF margin17.2%
EBITDA margin25.9%
Returns
ROE21.0%
ROA11.0%
ROIC (approx.)16.0%
Asset turnover0.56x
Leverage & solvency
Liabilities / assets47.3%
Debt / equity0.54x
Current ratio2.05x
Interest coverage15.46x
Cash quality & payout
Operating cash flow / net income1.12x
Accruals ratio-1.3%
Payout ratio19.9%
Capex / revenue4.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-07-31 | 2026Q22026-04-30 | 2026Q12026-01-31 | 2025Q4*2025-10-31 | 2025Q32025-07-31 | 2025Q22025-04-30 | 2025Q12025-01-31 | 2024Q4*2024-10-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.88B | $1.83B | $1.80B | $1.86B | $1.74B | $1.67B | $1.68B | $1.70B |
| Cost of revenue | $836.00M | $845.00M | $852.00M | $871.00M | $850.00M | $802.00M | $782.00M | $785.00M |
| Gross profit | $1.04B | $990.00M | $946.00M | $990.00M | $888.00M | $866.00M | $899.00M | $916.00M |
| R&D expense | $123.00M | $126.00M | $117.00M | $119.00M | $111.00M | $112.00M | $113.00M | $111.00M |
| SG&A expense | $475.00M | $465.00M | $476.00M | $428.00M | $417.00M | $454.00M | $410.00M | $397.00M |
| Operating income | $444.00M | $399.00M | $353.00M | $443.00M | $360.00M | $300.00M | $376.00M | $408.00M |
| Interest expense | $29.00M | $25.00M | $25.00M | $27.00M | $28.00M | $29.00M | $28.00M | $32.00M |
| Pretax income | $444.00M | $408.00M | $364.00M | $442.00M | $366.00M | $260.00M | $367.00M | $401.00M |
| Income tax | $82.00M | $69.00M | $59.00M | $8.00M | $30.00M | $45.00M | $49.00M | $50.00M |
| Net income | $362.00M | $339.00M | $305.00M | $434.00M | $336.00M | $215.00M | $318.00M | $351.00M |
| EBITDA | $510.00M | $466.00M | $420.00M | $514.00M | $432.00M | $373.00M | $448.00M | $477.00M |
| EPS (basic) | 1.28 | 1.20 | 1.08 | — | 1.18 | 0.75 | 1.12 | — |
| EPS (diluted) | 1.28 | 1.20 | 1.07 | — | 1.18 | 0.75 | 1.11 | — |
| Dividends declared per share | 0.26 | 0.26 | 0.26 | 0.25 | 0.25 | 0.25 | 0.25 | 0.24 |
| Weighted avg. shares (diluted) | 283.00M | 283.00M | 284.00M | — | 285.00M | 285.00M | 287.00M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $1.76B | $1.81B | $1.76B | $1.79B | $1.54B | $1.49B | $1.47B | $1.33B |
| Receivables | $1.48B | $1.50B | $1.52B | $1.49B | $1.38B | $1.37B | $1.33B | $1.32B |
| Inventory | $1.12B | $1.09B | $1.06B | $1.02B | $1.01B | $991.00M | $997.00M | $972.00M |
| Current assets | $4.69B | $4.76B | $4.62B | $4.59B | $4.25B | $4.21B | $4.11B | $3.96B |
| PP&E, net | $2.13B | $2.10B | $2.08B | $2.02B | $1.97B | $1.91B | $1.82B | $1.78B |
| Goodwill | $5.03B | $4.48B | $4.48B | $4.47B | $4.47B | $4.47B | $4.43B | $4.48B |
| Intangibles | $906.00M | $407.00M | $426.00M | $445.00M | $469.00M | $495.00M | $514.00M | $547.00M |
| Total assets | $13.97B | $13.06B | $12.81B | $12.73B | $12.23B | $12.16B | $11.91B | $11.85B |
| Current liabilities | $2.29B | $2.27B | $2.23B | $2.35B | $1.89B | $2.01B | $1.87B | $1.90B |
| Short-term debt | $304.00M | $304.00M | $304.00M | $304.00M | $59.00M | $146.00M | $16.00M | $45.00M |
| Long-term debt | $3.65B | $3.05B | $3.05B | $3.05B | $3.35B | $3.35B | $3.35B | $3.35B |
| Total debt | $3.95B | $3.35B | $3.35B | $3.35B | $3.41B | $3.50B | $3.36B | $3.39B |
| Total liabilities | $6.60B | $5.94B | $5.91B | $5.99B | $5.86B | $6.02B | $5.89B | $5.95B |
| Shareholders' equity | $7.36B | $7.12B | $6.91B | $6.74B | $6.37B | $6.14B | $6.03B | $5.90B |
| Net debt | $2.19B | $1.55B | $1.60B | $1.56B | $1.87B | $2.01B | $1.89B | $2.06B |
| Shares outstanding | 281.97M | 282.22M | 282.70M | 283.05M | 283.59M | 283.94M | 285.23M | 285.19M |
| Cash flow statement | ||||||||
| Operating cash flow | $519.00M | $277.00M | $268.00M | $545.00M | $362.00M | $221.00M | $431.00M | $481.00M |
| Capital expenditure | $80.00M | $76.00M | $93.00M | $93.00M | $103.00M | $114.00M | $97.00M | $93.00M |
| Free cash flow | $439.00M | $201.00M | $175.00M | $452.00M | $259.00M | $107.00M | $334.00M | $388.00M |
| Investing cash flow | -$1.03B | -$77.00M | -$93.00M | -$90.00M | -$96.00M | -$114.00M | -$94.00M | -$954.00M |
| Financing cash flow | $471.00M | -$144.00M | -$222.00M | -$200.00M | -$219.00M | -$116.00M | -$180.00M | $25.00M |
| Depreciation & amortization | $66.00M | $67.00M | $67.00M | $71.00M | $72.00M | $73.00M | $72.00M | $69.00M |
| Stock-based compensation | $31.00M | $34.00M | $41.00M | $26.00M | $32.00M | $30.00M | $40.00M | $26.00M |
| Dividends paid | $72.00M | $72.00M | $72.00M | $70.00M | $71.00M | $70.00M | $71.00M | $68.00M |
| Share buybacks | $78.00M | $65.00M | $152.00M | $85.00M | $85.00M | $165.00M | $90.00M | $335.00M |
Free plan shows the latest 8 periods; Pro shows all 73 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.